Maria E Taskinen 38th Lorne Cancer Conference 2026

Abstracts this author is presenting:

• Clinical candidate drug NXP800 inhibits HSF1 pathway and activates the Integrated Stress Response (ISR) via GCN2 in ARID1A mutant ovarian cancer — Poster Session 2